Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print November 5, 2008, doi:10.1212/01.wnl.0000327098.86861.d4)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Italian Translation
Right arrow Japanese Translation
Right arrow All Versions of this Article:
01.wnl.0000327098.86861.d4v1
72/2/110    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lohmann, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lohmann, E.
Related Collections
Right arrowRelated Article
Received March 10, 2008
Accepted June 27, 2008

A multidisciplinary study of patients with early onset PD with and without parkin mutations

E. Lohmann MD, S. Thobois MD, PhD, S. Lesage PhD, E. Broussolle MD, PhD, S. Tezenas du Montcel MD, PhD, M.-J. Ribeiro PhD, P. Remy MD, PhD, A. Pelissolo MD, B. Dubois MD, L. Mallet MD, P. Pollak MD, PhD, Y. Agid MD, PhD, A. Brice MD*, The French Parkinson's Disease Genetics Study Group

From INSERM (E.L., S.L., Y.A., A.B.), UMR_S679 Neurologie & Thérapeutique Expérimentale, Paris; AP-HP (E.L., B.D., Y.A., A.B.), Pitié-Salpêtrière Hospital, Department of the Nervous System Disorders, Paris; UPMC Univ Paris 06 (E.L., S.L., Y.A., A.B.), UMR_S679, Paris; University of Lyon I and INSERM UMR 864 and The Pierre Wertheimer Neurological Hospital (S.T., E.B.), Department of Neurology, Lyon; AP-HP (S.T.d.M.), Pitié-Salpêtrière Hospital, Department of Public Health, Unit of de Biostatistics and Medical Information and Unit of Medical Research, Paris; UPMC Univ Paris 06 (S.T.d.M.), EA3974 Modelisation in Clinical Research, Paris; CEA (M.-J.R.), I2BM, Service Hospitalier Frédéric Joliot, Orsay; CEA (P.R.), I2BM, URA-CEA-CNRS 2210, Orsay; CHU Henri Mondor (P.R.), AP-HP et Faculté de Médecine Paris 12, Créteil; AP-HP (A.P.), Pitié-Salpêtrière Hospital, Department of Psychiatry, Paris; INSERM UMR 610 Neuroanatomie Fonctionnelle du Comportement et de ses Troubles (B.D.), Paris; AP-HP (B.D.), Pitié-Salpêtrière Hospital, Centre de Référence sur la Maladie de Pick, Paris; Inserm Avenir Group IFR 70 Behaviour (L.M.), Emotion and Basal Ganglia, Center of Clinical Investigation, Paris; Department of Clinical and Biological Neurosciences (P.P.), University Hospital of Grenoble; AP-HP (Y.A.), Pitié-Salpêtrière Hospital, Clinical Investigation Center, Paris; and AP-HP (A.B.), Pitié-Salpêtrière Hospital, Department of Genetics and Cytogenetics, Paris, France.


* To whom correspondence should be addressed. E-mail: alexis.brice{at}upmc.fr.

Objective: To establish phenotype–genotype correlations in early onset Parkinson disease (EOPD), we performed neurologic, neuropsychological, and psychiatric evaluations in a series of patients with and without parkin mutations.

Background: Parkin (PARK2) gene mutations are the major cause of autosomal recessive parkinsonism. The usual clinical features are early onset typical PD with a slow clinical course, an excellent response to low doses of levodopa, frequent treatment-induced dyskinesias, and the absence of dementia.

Methods: A total of 44 patients with EOPD (21 with and 23 without parkin mutations) and 9 unaffected single heterozygous carriers of parkin mutations underwent extensive clinical, neuropsychological, and psychiatric examinations.

Results: The neurologic, neuropsychological, and psychiatric features were similar in all patients, except for significantly lower daily doses of dopaminergic treatment and greater delay in the development of levodopa-related fluctuations (p < 0.05) in parkin mutation carriers compared to noncarriers. There was no major difference between the two groups in terms of general cognitive efficiency. Psychiatric manifestations (depression) were more frequent in patients than in healthy single heterozygous parkin carriers but did not differ between the two groups of patients.

Conclusion: Carriers of parkin mutations are clinically indistinguishable from other patients with young-onset Parkinson disease (PD) on an individual basis. Severe generalized loss of dopaminergic neurons in the substantia nigra pars compacta in these patients is associated with an excellent response to low doses of dopa-equivalent and delayed fluctuations, but cognitive impairment and special behavioral or psychiatric symptoms were not more severe than in other patients with PD with early onset.


Related Article

Parkinson disease(s): Is "Parkin disease" a distinct clinical entity?
Christine Klein and Katja Lohmann
Neurology 2009 72: 106-107. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNMHome page
M.-J. Ribeiro, S. Thobois, E. Lohmann, S. T. du Montcel, S. Lesage, A. Pelissolo, B. Dubois, L. Mallet, P. Pollak, Y. Agid, et al.
A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations
J. Nucl. Med., August 1, 2009; 50(8): 1244 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Klein and K. Lohmann
Parkinson disease(s): Is "Parkin disease" a distinct clinical entity?
Neurology, January 13, 2009; 72(2): 106 - 107.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.